CJASN
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
QUICK SEARCH:   [advanced]


     

Published ahead of print on October 19, 2005
Clinical Journal of the American Society of Nephrology
© 2005 American Society of Nephrology
doi: 10.2215/CJN.00330705
This Article
Right arrow Full Text (Rapid PDF)
Right arrow All Versions of this Article:
CJN.00330705v1
1/1/148    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Grantham, J. J.
Right arrow Articles by Torres, V. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grantham, J. J.
Right arrow Articles by Torres, V. E.
Related Collections
Right arrowRelated Article

Editorials

Volume Progression in Autosomal Dominant Polycystic Kidney Disease: The Major Factor Determining Clinical Outcomes

Jared J. Grantham *1, Arlene B. Chapman {dagger}, and Vicente E. Torres {ddagger}

*Kansas University Medical Center, Kansas City, Kansas; {dagger}Emory University, Atlanta, Georgia; and {ddagger}Mayo Clinic College of Medicine, Rochester, Minnesota


1 To whom correspondence should be addressed. E-mail: jgrantha{at}kumc.edu.


  Abstract

Autosomal dominant polycystic kidney disease (PKD) is a hereditary condition characterized by the progressive enlargement of innumerable renal cysts that contribute to life-altering morbidity early in the course of the disease. Evidence indicates that the rate of increase in kidney volume can be reliably measured by magnetic resonance or computed tomography imaging, thus providing objective means to judge the effectiveness of therapies that are targeted to the aberrant growth of renal tubules. It is now possible, therefore, to monitor the effectiveness of potential therapies on the signature abnormality in autosomal dominant PKD before irreversible damage has been done by the cysts. Evidence accumulated from human cross-sectional and longitudinal studies and longitudinal studies of PKD models in animals provide strong support for the view that reducing the rate of kidney volume enlargement will ameliorate the late-stage development of renal insufficiency.

Related Article

Calcium Restores a Normal Proliferation Phenotype in Human Polycystic Kidney Disease Epithelial Cells
Tamio Yamaguchi, Scott J. Hempson, Gail A. Reif, Anne-Marie Hedge, and Darren P. Wallace
J. Am. Soc. Nephrol. 2006 17: 178-187. [Abstract] [Full Text] [PDF]



This article has been cited by other articles:


Home page
 CJASNHome page
D. Rizk, C. Jurkovitz, E. Veledar, S. Bagby, D. A. Baumgarten, F. Rahbari-Oskoui, T. Steinman, and A. B. Chapman
Quality of Life in Autosomal Dominant Polycystic Kidney Disease Patients not yet on Dialysis
Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 560 - 566.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. J. Grantham
Autosomal Dominant Polycystic Kidney Disease
N. Engl. J. Med., October 2, 2008; 359(14): 1477 - 1485.
[Full Text] [PDF]

Home page
 CJASNHome page
J. P. Calvet
Strategies to Inhibit Cyst Formation in ADPKD
Clin. J. Am. Soc. Nephrol., July 1, 2008; 3(4): 1205 - 1211.
[Abstract] [Full Text] [PDF]

Home page
 Nephrol Dial TransplantHome page
T. I. Steinman
Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease
Nephrol. Dial. Transplant., February 1, 2008; 23(2): 431 - 433.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Copyright © 2005 by the American Society of Nephrology.